scholarly journals Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial

2020 ◽  
Vol 31 (12) ◽  
pp. 1709-1718 ◽  
Author(s):  
K. Kalinsky ◽  
J.R. Diamond ◽  
L.T. Vahdat ◽  
S.M. Tolaney ◽  
D. Juric ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase I ◽  
Hormone Receptor ◽  
Metastatic Breast ◽  
Hormone Receptor Positive ◽  
Previously Treated ◽  
Basket Trial

Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR+) metastatic breast cancer (MBC).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 531-531
Author(s):  
Antoinette R. Tan ◽  
Serena Tsan-Lai Wong ◽  
Robert D. Warren ◽  
Jennifer Eng-Wong ◽  
Minetta C. Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase I ◽  
Hormone Receptor ◽  
Metastatic Breast ◽  
First Line ◽  
First Line Therapy ◽  
Hormone Receptor Positive ◽  
Line Therapy

scholarly journals Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer

2021 ◽  
Vol 154 ◽  
pp. 11-20
Author(s):  
Yuan Yuan ◽  
Jin Sun Lee ◽  
Susan E. Yost ◽  
Paul H. Frankel ◽  
Christopher Ruel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase I ◽  
Hormone Receptor ◽  
Metastatic Breast ◽  
Hormone Receptor Positive
Sign in / Sign up

Export Citation Format

Share Document